八月 2026
- Home
- Tetrapharm
八月 2026的Tetrapharm市场份额分析
TETRAPHARM was founded in 2018 by Martin Rose and Jesper Breum who both held leading positions in a number of global pharmaceutical companies.
With a strong foundation in biotech and CNS, our primary focus is to design and develop next generation drugs for the treatment of neurological disorders.
Tetrapharm(包含公司地区分支机构)
查看更多网站流量和参与度信息- tetrapharm.eu
Tetrapharm热门域名的总访问量
了解Tetrapharm市场份额和潜在市场覆盖范围。
过去 3 个月的总访问量
子公司明细
Tetrapharm热门域名的平均访问时长
分析Tetrapharm参与度指标。
过去 3 个月的平均访问时长
子公司明细
Tetrapharm热门域名的平均页面浏览量
了解Tetrapharm如何保持用户参与度、培养用户兴趣和鼓励采取后续操作。
过去 3 个月的平均页面浏览量
子公司明细
想要获取更深入的流量洞见?
过滤超过 2030 万家在线企业。发现流量激增的新潜在客户,开始或停止使用技术的新潜在客户,或者获得正面报道的新潜在客户。
Tetrapharm 的新闻与信号
借助 Similarweb 销售信号提醒,每当在目标受众之中出现新的机会或威胁时,您都会收到所识别出购买信号的每日更新。
新闻Tetra Pharm launches preclinical data for TPC-026, a novel compound for the chronic treatment of multiple metabolic disorders.TETRAPHARM, a Copenhagen-based biopharmaceutical company, has announced promising preclinical data for TPC-026, a novel compound for the chronic treatment of multiple metabolic disorders, including obesity.
一月 28, 2026阅读更多
新闻DanCann partnered with Tetra Pharm on Mar 13th '25.COPENHAGEN, Denmark, 13 March 2025 - DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the "Company"), a Danish company powered by cannabinoids, is pleased to announce a strategic partnership with Tetra Pharm Technologies ApS ("Tetra Pharm Technologies").
三月 13, 2025阅读更多
新闻Rootstock signed new client Tetra Pharm on Nov 14th '24.November 15, 2024 Tetra Pharm Technologies selects Rootstock ERP.
十一月 15, 2024阅读更多
查看 Tetrapharm 的所有信号
让您的销售团队专注于最有希望的机会。通过分清机会的轻重缓急并在合适的时机介入,您可以优化工作并达成更多交易。
